Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial

Mikhail Kosiborod, Sheryl L. Windsor, Orly Vardeny, Jeffrey S. Berger, Harmony R Reynolds, Stavroula Boumakis, Andrew D. Althouse, Scott D. Solomon, Ankeet S. Bhatt, Alexander Peikert, James F. Luther, Eric Leifer, Andrei Kindzelski, Mary Cushman, Michelle N. Gong, Lucy Z. Kornblith, Pooja Khatri, Keri S. Kim, Lisa Baumann Kreuziger, Ali Javaheri, Carlos Carpio, Lana Wahid, Jose Lopez-Sendon Moreno, Álvaro Alonso, Minh Q. Ho, José López‐Sendón, Renato D. Lópes, Jeffrey L. Curtis, Bridget‐Anne Kirwan, Mark W. Geraci, Matthew D. Neal, Judith S. Hochman, PR Avancini Caramori, M Esteves Hernandes, S Babudieri, M Contoli, M Fernando, JR Gonzalez Juanatey, F Ibañez Estellez, E Mateos, M Tidswell, O Akala, M Pursley, A Jathavedam, J Markley, M Gelman, Z Ajani, F Mackay, K Kunisaki, K Martin, M Exline, J Huggins, L Nicholson, G Lim, M Aboudara, R Sherwin, S Torbati, J Wilson, JG Latorre, J Busch, T Albertson, M Matthay, S Gandotra, B Joseph, K Hudock, N Iovine, J Quigley, R Hyzy, M Kutcher, D Huang, A Pandey, J Sheehan, N Solankhi, D Huang, W Rodriguez, B Shah, A Khanna, G Bochicchio, M McCarthy, S Pan, P Balasubraman